Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that data from its ongoing Phase 1 trial of KB004, an anti-EphA3 monoclonal antibody (mAb), will be presented at a poster session at the 55th American Society of Hematology (ASH) Annual Meeting and Exhibition. The Phase 1 trial of KB004 is a multi-center, dose-escalation study evaluating KB004 in patients with advanced hematologic malignancies. The presentation will include data describing the safety, pharmacokinetics and clinical activity of KB004. The ASH meeting is being held in New Orleans, Louisiana from December 7 – 10, 2013.

(Logo:  http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

"This presentation will describe the safety profile observed in our ongoing Phase 1 trial of KB004, as well as reductions in markers of disease activity, peripheral blood blast percentage and marrow blast percentage," stated Dr. Nestor A. Molfino, Chief Medical Officer at KaloBios.  "We believe these early data support the potential of KB004 in EphA3 positive hematologic malignancies, and we are targeting enrolling the first patient in the Phase 2 portion of the study of this antibody by the end of 2013."

Poster Presentation Details

  • Title: A Phase I study of KB004, a novel non-fucosylated humaneered® antibody, targeted against the receptor tyrosine kinase EphA3, in advanced hematologic malignancies
  • Date: Monday, December 7,, 2013
  • Presentation Time: 6:00 p.m. – 8:00 p.m. 
  • Presenter: Jeffrey Lancet, MD, Medical Oncology, H. Lee Moffitt Cancer Center and Research Ins
    '/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Cell therapy using patients own bone marrow may present option for heart disease
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Entomology 2012 to present 105 insect symposia in November
4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
5. The Brain Prize 2012 is presented May 9th
6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
9. Coral reef experts to present latest coral reef science during July symposium
10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... SPRINGS, Florida , July 1, 2014 ... wallets pave way for convenience and improved security: NXT-ID, Inc. ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) ... is pleased to announce that the second series of 30 ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... able to change their spots, but corals can change their ... chemical composition of the seawater around them. , That's the ... writing in the July issue of the journal Geology. ... is the first known case of an animal altering the ...
... born infected with human cytomegalovirus, or CMV, and about ... the virus ?almost one an hour. These disabilities can ... of coordination, and seizures. According to the Centers for ... cause of serious disability as Down syndrome, fetal alcohol ...
... Biologists from Washington University in St. Louis and their ... trees of rice varieties and have determined that the ... Asian locales. , Jason Londo, Washington University in Arts ... A. Schaal, Ph.D., Washington University Spencer T. Olin Professor ...
Cached Biology News:Corals switch skeleton material as seawater changes 2Corals switch skeleton material as seawater changes 3Innovative method for creating a human cytomegalovirus vaccine outlined 2Biologists find regions of rice domestication 2
(Date:7/10/2014)... in the fight against terrorism with the creation of ... with the use of light and special glass fibres. ... B: Chemical , the researchers describe a novel optical ... low as 6.3 ppm (parts per million). It requires ... "Traditionally explosives detection has involved looking for metals that ...
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... spiders can sit upside down forever. Nanophysics makes sure of ... an article just published in Physical Review E . ... and spiders that seem to be able to sit still ... for many years. We will soon be able to buy ... gecko,s foot. But the fact is, sooner or later the ...
(Date:7/10/2014)... The new alliance will see the two universities and ... working with business and industry and their complementary academic ... will help to shape the scientific priorities of the ... train up to 300 high-calibre PhD students, will provide ... at NPL, the potential of the Laboratory will be ...
Breaking Biology Technology:Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2Even geckos can lose their grip 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
... , MALVERN, Pa. ... (AMR) and Decision Resources find that the leading driver ... broad-spectrum activity against gram-positive and gram-negative pathogens. Due to ... surveyed European physicians reveal that they look primarily for ...
... ... Top LASIK surgeons and recognized refractive and cataract surgery ... up-to-date on the latest developments in vision correction surgery, cataract surgery, ... Ophthalmology (AAO) annual meeting in San Francisco, California. Dr. Richard Lindstrom, ...
... VIENNA, Austria, November 19 AFFiRiS AG ... an unexpectedly early,stage of development: the vaccine candidate AD02 is ... This decision by the company,immediately follows the completion of two ... based its fast decision on the first interim,analysis of the ...
Cached Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3